COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know Up to 2023?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Feb 24

PMID 38396888

Authors

Agata Michalak

Tomasz Lach

Karolina Szczygiel

Halina Cichoz-Lach

Affiliations

Soon will be listed here.

Abstract

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related to diverse extrapulmonary manifestations of this pathology. The liver was found to be a relatively common organ, beyond the respiratory tract, affected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed the essential role of chronic liver disease (CLD) in the general outcome of coronavirus infection. Present concerns in this field are related to the direct hepatic consequences caused by COVID-19 and pre-existing liver disorders as risk factors for the severe course of the infection. Which mechanism has a key role in this phenomenon-previously existing hepatic disorder or acute liver failure due to SARS-CoV-2-is still not fully clarified. Alcoholic liver disease (ALD) constitutes another not fully elucidated context of coronavirus infection. Should the toxic effects of ethanol or already developed liver cirrhosis and its consequences be perceived as a causative or triggering factor of hepatic impairment in COVID-19 patients? In the face of these discrepancies, we decided to summarize the role of the liver in the whole picture of coronavirus infection, paying special attention to ALD and focusing on the pathological pathways related to COVID-19, ethanol toxicity and liver cirrhosis.

References

Muhovic D, Bojovic J, Bulatovic A, Vukcevic B, Ratkovic M, Lazovic R . First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020; 40(8):1901-1905. PMC: 7276916. DOI: 10.1111/liv.14516. View

Shousha H, Afify S, Maher R, Asem N, Fouad E, Mostafa E . Hepatic and gastrointestinal disturbances in Egyptian patients infected with coronavirus disease 2019: A multicentre cohort study. World J Gastroenterol. 2021; 27(40):6951-6966. PMC: 8567470. DOI: 10.3748/wjg.v27.i40.6951. View

Brandi N, Spinelli D, Granito A, Tovoli F, Piscaglia F, Golfieri R . COVID-19: Has the Liver Been Spared?. Int J Mol Sci. 2023; 24(2). PMC: 9866733. DOI: 10.3390/ijms24021091. View

Brito C, Barros F, Lopes E . Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?. World J Hepatol. 2020; 12(8):413-422. PMC: 7475779. DOI: 10.4254/wjh.v12.i8.413. View

Ciobanu A, Gherasim L . Ischemic Hepatitis - Intercorrelated Pathology. Maedica (Bucur). 2018; 13(1):5-11. PMC: 5972787. View

Mougharbel F, Sampasa-Kanyinga H, Heidinger B, Corace K, Hamilton H, Goldfield G . Psychological and Demographic Determinants of Substance Use and Mental Health During the COVID-19 Pandemic. Front Public Health. 2021; 9:680028. PMC: 8270652. DOI: 10.3389/fpubh.2021.680028. View

Beraldo R, Marcondes M, Dos Santos M, Grillo T, Pires G, de Oliveira C . COVID-19 in a Patient with Liver Cirrhosis. Am J Case Rep. 2021; 22:e929948. PMC: 7959101. DOI: 10.12659/AJCR.929948. View

Boraschi P, Giugliano L, Mercogliano G, Donati F, Romano S, Neri E . Abdominal and gastrointestinal manifestations in COVID-19 patients: Is imaging useful?. World J Gastroenterol. 2021; 27(26):4143-4159. PMC: 8311532. DOI: 10.3748/wjg.v27.i26.4143. View

Chen Y, Xu Y, Zhang K, Shen L, Deng M . Ferroptosis in COVID-19-related liver injury: A potential mechanism and therapeutic target. Front Cell Infect Microbiol. 2022; 12:922511. PMC: 9363633. DOI: 10.3389/fcimb.2022.922511. View

10.

Spogis J, Hagen F, Thaiss W, Hoffmann T, Malek N, Nikolaou K . Sonographic findings in coronavirus disease-19 associated liver damage. PLoS One. 2021; 16(2):e0244781. PMC: 7894893. DOI: 10.1371/journal.pone.0244781. View

11.

Kapuria D, Gangu K, Chourasia P, Boba A, Nguyen A, Ryu M . COVID-19 Alcoholic Cirrhosis and Non-Alcoholic Steatohepatitis Cirrhosis Outcomes among Hospitalized Patients in the United States: Insight from National Inpatient Sample Database. Trop Med Infect Dis. 2022; 7(12). PMC: 9786037. DOI: 10.3390/tropicalmed7120421. View

12.

Gracia-Ramos A, Jaquez-Quintana J, Contreras-Omana R, Auron M . Liver dysfunction and SARS-CoV-2 infection. World J Gastroenterol. 2021; 27(26):3951-3970. PMC: 8311530. DOI: 10.3748/wjg.v27.i26.3951. View

13.

Bhangui P . Impact of the COVID-19 Pandemic on Patients with End-Stage Liver Disease: One Virus-A Plethora of Consequences. J Clin Exp Hepatol. 2023; 13(5):725-727. PMC: 10482993. DOI: 10.1016/j.jceh.2023.07.007. View

14.

Kuo Y, Kwo P, Wong R, Singal A . Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications. J Clin Transl Hepatol. 2022; 11(1):130-135. PMC: 9647098. DOI: 10.14218/JCTH.2022.00129. View

15.

Baiges A, Cerda E, Amicone C, Tellez L, Alvarado-Tapias E, Puente A . Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases. Clin Gastroenterol Hepatol. 2021; 20(7):1525-1533.e5. PMC: 8710430. DOI: 10.1016/j.cgh.2021.12.032. View

16.

Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S . Serum Iron Level as a Potential Predictor of Coronavirus Disease 2019 Severity and Mortality: A Retrospective Study. Open Forum Infect Dis. 2020; 7(7):ofaa250. PMC: 7337740. DOI: 10.1093/ofid/ofaa250. View

17.

Ali F, Mohammedsaleh Z, Ali M, Ghogar O . Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol. 2021; 27(15):1531-1552. PMC: 8058655. DOI: 10.3748/wjg.v27.i15.1531. View

18.

Ding Z, Li G, Chen L, Shu C, Song J, Wang W . Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2020; 74(6):1295-1302. PMC: 7749734. DOI: 10.1016/j.jhep.2020.12.012. View

19.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L . SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4):807-816. PMC: 7211738. DOI: 10.1016/j.jhep.2020.05.002. View

20.

de Jesus R, de Carvalho J, de Oliveira L, Cunha C, Alves T, Vieira S . Metabolic and nutritional triggers associated with increased risk of liver complications in SARS-CoV-2. World J Hepatol. 2022; 14(1):80-97. PMC: 8790394. DOI: 10.4254/wjh.v14.i1.80. View